| Authors: |
Lumeau A; Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK., Pfuderer PL; Department of Pathology, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Centre, Li Ka Shing Centre, Cambridge, UK., Scarth JA; Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK., Maniati E; Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK., Guscott MA; Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK., Shaikh N; Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK., Copley FB; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Gerdes H; Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK., De Angelis S; Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK., Alard EL; Centre for Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.; Department of Biochemistry, University of Oxford, Oxford, UK., Wang J; Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK., Cutillas PR; Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK., Mardakheh FK; Department of Biochemistry, University of Oxford, Oxford, UK., Boemo MA; Department of Pathology, University of Cambridge, Cambridge, UK.; Department of Genetics, University of Cambridge, Cambridge, UK., Forment JV; DDR Biology, Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., McClelland SE; Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK. s.mcclelland@qmul.ac.uk. |
